| Literature DB >> 31719772 |
Gustavo Fernandez-Ranvier1, Aryan Meknat2, Daniela E Guevara3, William B Inabnet1.
Abstract
BACKGROUND: Remote-access thyroid surgery has gained popularity and has advanced significantly over the past two decades, given the patient desire to avoid cosmetically displeasing scarring. It has only been recently that natural-orifice transluminal endoscopic surgery (NOTES) techniques have been geared for thyroidectomies. The transoral endoscopic thyroidectomy vestibular approach has been categorized as a NOTES procedure-given the approach to the thyroid gland via incisions in the oral cavity. Our aim is to provide a review of the current literature on the transoral endoscopic thyroidectomy vestibular approach (TOETVA), to present the worldwide experience of this novel procedure, and to outline whether individual patients have characteristics that would make the procedure feasible for this technique.Entities:
Mesh:
Year: 2019 PMID: 31719772 PMCID: PMC6830499 DOI: 10.4293/JSLS.2019.00036
Source DB: PubMed Journal: JSLS ISSN: 1086-8089 Impact factor: 2.172
Literature Review of Experiences with TOETVA
| Author | Cases, N | Indications for Thyroidectomy | Surgery Type | Tumor Size, cm, Mean (Range) | Antibiotics | Conversion to Open | Hospital Stay, Days (Range) |
|---|---|---|---|---|---|---|---|
| Nakajo et al | 8 | 3 FA | TOVANS: Extension NS | NS | 3 days | 0 | 4.5 (4–5) |
| 1 NG | |||||||
| 3 mPTC | |||||||
| 1 FC | |||||||
| Wang et al | 12 | 3 Hyperplastic nodules | TOETVA: Lobectomy and total thyroidectomy | 3.2 (1–4.6) | NS | 0 | 4.9 (3.5–6.3) |
| 3 Follicular nodules | |||||||
| 4 Colloid nodules | |||||||
| 2 Follicular adenomas | |||||||
| Yang et al | 41 | 34 benign goiters | TOETVA: Lobectomy, subtotal or near total resection | 3.5 (2.8–4.1) | At induction of anesthesia + 3 days postoperative | 0 | 5 |
| 3 hyperthyroidism | |||||||
| 4 PTC | |||||||
| Anuwong et al | 60 | 34 single nodules | TOETVA: Total thyroidectomy, lobectomy | 5.4 (3–10) | At induction: Augmentin (1.2 gm) | 0 | 3.6 (2–7) |
| 22 MNG | Postoperative: 2 days IV abx + 5 days PO abx | ||||||
| 2 Graves | |||||||
| 2 PTC | |||||||
| Pai et al. 2015 | 1 | 1 single adenoma | TOETVA: Lobectomy | 4 | Postoperative oral abx | 0 | 7 |
| Jitpratoom et al | 45 | 45 Grave's | TOETVA: Total thyroidectomy | Thyroid size: 5.41 (4–6.8) | At induction: Augmentin (1.2 gm) | 1 (for excessive bleeding-excluded) | 3 |
| Postoperative: 2 days IV abx + 5 days PO abx | |||||||
| Park JO et al | 1 | 1 FN | TOETVA: Lobectomy | 2 | Cephalosporin (2nd generation) IV 2 days | 0 | 3 |
| PO ABX 7 days | |||||||
| Wang et al | 10 | 5 Suspicious lesions | TOETVA: Total thyroidectomy, lobectomy + selective CND | 0.7 (0.4–1.3) | At induction + 3 days of IV abx | 0 | 4 (3–5) |
| 1 FN | |||||||
| 4 PTC | |||||||
| Zeng et al. 2016 | 4 | 4 MNG | TOETVA | 5 | NS | NS | 5 |
| Udelsman et al | 7 | 1 MNG | TOETVA: Total thyroidectomy, lobectomy | 4.2 (2.3–5.2) | Yes, N/S | 0 | 1.1 (1–2) |
| 1 HCN | |||||||
| 1 Hyperplastic nodule | |||||||
| 1 toxic adenoma | |||||||
| 1 mPTC + colloid nodules | |||||||
| 2 Parathyroids | |||||||
| Inabnet et al | 1 | 1 toxic adenoma | TOETVA: Lobectomy | 2.8 | Yes | 0 | 1 |
| Dionigi et al | 15 | 6 FLUS (1 PTC on final pathology) | TOETVA: Total thyroidectomy, lobectomy | 1.9 (1.3–3.2) | At induction of anesthesia and 5 days post-op | 0 | 1.6 (1–4) |
| 2 toxic adenomas | |||||||
| 5 NG | |||||||
| 1 Hurthle cell adenoma | |||||||
| 1 PTC | |||||||
| Richmond & Kim. 2017 | 17 | 5 benign | TORTVA: Lobectomy & CND in 13 cases | 1.2 (0.9–2.5) | NS | 1 (for a large substernal goiter) | NS |
| 11 PTC | |||||||
| Russell et al | 14 | 5 adenomatous nodules | TORTVA (6 cases): Lobectomy | 3.2 (1.5–4.3) | Augmentin (875 mg twice daily) 5 days | 0 | 1 pt: SDS |
| 4 AUS | TOETVA (6 cases): Lobectomy | 13 pts: 23-hour admission | |||||
| 1 HCN | |||||||
| 1 FN | |||||||
| 1 PTC | |||||||
| 2 parathyroids | |||||||
| Anuwong et al | 422 | 245 single adenoma | TOETVA: Lobectomy & total thyroidectomy | 3.8 (1–10) | At induction: Augmentin (1.2 gm) | 3 (for excessive bleeding - excluded) | 3 |
| 118 MNG | Postoperative: 2 days IV ABX + 5 days PO Abx | ||||||
| 33 Grave's | |||||||
| 26 mPTC | |||||||
| Park & Sun | 18 | 2 AUS | TOETVA: | 1.75 (0.5–7.5) | IV 2 days + | 0 | 4 (3–7) |
| 2 FN | Lobectomy, completion, total thyroidectomy | 7 days PO (type NS) | |||||
| 1 benign | |||||||
| 1 completion (FC) | |||||||
| 1 suspicious | |||||||
| 11 PTC | |||||||
| Anuwong et al | 200 | 111 single adenoma | TOETVA: Total thyroidectomy, lobectomy | 4.1 (1–10) | At induction: Augmentin (1.2 gm) | 1 (for excessive bleeding—excluded) | 3.2 (2–5) |
| 66 MNG | Postoperative: 2 days IV ABX + 5 days PO ABX | ||||||
| 12 Grave's | |||||||
| 11 mPTC | |||||||
| Yi et al. 2018 | 20 | 19 PTCs | TOETVA: Total thyroidectomy, lobectomy, and wide isthusectomy | 0.8 (0.2–1.4) | At induction: IV 3rd-generation cephalosporin + 7 days of oral Abx (Augmentin) | 0 | 4.7 (3–20) |
| 1 Follicular neoplasm | |||||||
| Razavi et al. 2018 | 1 | 1 Hurthle cell carcinoma | TOETVA: Completion thyroidectomy | 2.0 | NS | 0 | NS |
| Tesseroli et al. 2018 | 9 | 7 benign adenomas | TOETVA: Total thyroidectomy, lobectomy | 2.3 (1–4) | 24 hours of clindamycin | 0 | 0.8 (0–1) |
| 2 PTCs |
Abx: antibiotic; AUS, atypia of indeterminate significance; CND, central neck dissection; FA, follicular adenoma; FC, follicular cancer; FLUS, follicular lesion of undetermined significance; FN, follicular neoplasm; HCN, Hurthle cell neoplasm; IV, intravenous; MNG, multinodular goiter; mPTC, micro papillary thyroid carcinoma; NG, nodular goiter; NS, not specified; PO, per oral; PTC, papillary thyroid carcinoma; SDS, same-day surgery; TOETVA, transoral endoscopic thyroidectomy vestibular approach; TORTVA, transoral robotic thyroidectomy vestibular approach; TOVANS, transoral video-assisted neck surgery.
All confirmed to be PTC on pathology.
Patient Eligibility for TOETVA
| Favorable features | Patient's own motivation to avoid a cervical scar |
| Symptomatic benign nodules ≥6 cm. (Benign nodules >6 cm or <10 cm is possible but may require surgical expertise in TOETVA) | |
| Cytologically indeterminate nodules (Bethesda 3 or 4 lesions) <6 cm | |
| Estimated thyroid diameter ≤10 cm on ultrasound | |
| Estimated gland volume ≤45 mL on ultrasound | |
| Symptomatic Hashimoto's thyroiditis | |
| Grave's disease (euthyroid, if possible) | |
| Differentiated thyroid cancer <3 cm without extrathyroidal extension or lymph node metastasis on preoperative ultrasonography | |
| Not favorable features | Substernal goiters |
| Previous neck and chin surgery | |
| Previous neck radiation |
Complications That Have Been Documented in the Literature
| Complications | Remarks | |
|---|---|---|
| Cutaneous lesions | Ecchymosis, full thickness tears, burns | The postoperative bruising and ecchymosis generally resolves in one to two weeks. However, full-thickness injuries or burns may not resolve and can leave a scar. |
| Nerve Injuries | Mental nerve | Of the reported mental nerve injuries, only a minority had persistent (>6 months) lower lip and/or chin numbness/paresthesia. There was a decrease in incidence after adjustment of vestibular port placement—of the 3 reported, recovery occurred within 4 months. |
| Recurrent laryngeal nerve | There has been a low incidence of RLN injury. In all reported cases of injury to the RLN, via TOETVA, a full recovery of vocal cord function was reported within 6 months of surgery. | |
| Hypoparathyroidism | Transient | Transient hypoparathyroidism has been observed in up to 22% of the patients in a series of total thyroidectomies for the treatment of Grave's disease. |
| Conversion rate | Endoscopic to open or Robotic to endoscopic | A small number of TOETVAs have been converted to open procedures—most commonly as a result of excessive bleeding or greater than anticipated nodular size. |
| Hematoma | Immediately postop versus days to weeks later | To date, a very limited number of postoperative hematomas have been reported in the literature. |
| Seroma | Postoperative seromas has been observed in 20 patients from a total of 425 in the largest series published to date. All cases were resolved with simple needle aspiration | |
| SSI | Surgical site infection | There have been 2 reported SSI |
RLN, recurrent laryngeal nerve; SSI, surgical site infection; TOETVA, transoral endoscopic thyroidectomy vestibular approach.